Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT ID: NCT02536404

Last Updated: 2021-11-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-25

Study Completion Date

2018-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Etrasimod 2 mg

Group Type EXPERIMENTAL

Etrasimod

Intervention Type DRUG

Placebo

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etrasimod

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

APD334

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who completed the APD334-003 (NCT02447302) study

Exclusion Criteria

* Participants who did not complete the APD334-003 study
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Arena Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arena CT.gov Administrator

Role: STUDY_DIRECTOR

Arena Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arena 1119

Birmingham, Alabama, United States

Site Status

Arena 1133

Dothan, Alabama, United States

Site Status

Arena 1143

Thousand Oaks, California, United States

Site Status

Arena 1107

Hollywood, Florida, United States

Site Status

Arena 1138

Miami, Florida, United States

Site Status

Arena 1123

Naples, Florida, United States

Site Status

Arena 1141

Orlando, Florida, United States

Site Status

Arena 1106

Port Orange, Florida, United States

Site Status

Arena 1137

Sweetwater, Florida, United States

Site Status

Arena 1131

Chicago, Illinois, United States

Site Status

Arena 1139

Hoffman Estates, Illinois, United States

Site Status

Arena 1127

Urbana, Illinois, United States

Site Status

Arena 1113

Chevy Chase, Maryland, United States

Site Status

Arena 1142

Traverse City, Michigan, United States

Site Status

Arena 1111

Troy, Michigan, United States

Site Status

Arena 1109

Great Neck, New York, United States

Site Status

Arena 1114

Rochester, New York, United States

Site Status

Arena 1118

Raleigh, North Carolina, United States

Site Status

Arena 1112

Cincinnati, Ohio, United States

Site Status

Arena 1117

Pittsburgh, Pennsylvania, United States

Site Status

Arena 1105

Germantown, Tennessee, United States

Site Status

Arena 1102

Hermitage, Tennessee, United States

Site Status

Arena 1136

DeSoto, Texas, United States

Site Status

Arena 1121

Houston, Texas, United States

Site Status

Arena 1116

Temple, Texas, United States

Site Status

Arena 1103

Ogden, Utah, United States

Site Status

Arena 1130

Richmond, Virginia, United States

Site Status

Arena 1128

Roanoke, Virginia, United States

Site Status

Arena 1115

Seattle, Washington, United States

Site Status

Arena 1101

Seattle, Washington, United States

Site Status

Arena 1108

Wauwatosa, Wisconsin, United States

Site Status

Arena 1604

Kingswood, , Australia

Site Status

Arena 1605

Randwick, , Australia

Site Status

Arena 1607

Subiaco, , Australia

Site Status

Arena 1490

Vienna, , Austria

Site Status

Arena 1472

Edegem, , Belgium

Site Status

Arena 1464

Kortrijk, , Belgium

Site Status

Arena 1473

Leuven, , Belgium

Site Status

Arena 1421

Rousse, , Bulgaria

Site Status

Arena 1417

Sofia, , Bulgaria

Site Status

Arena 1410

Sofia, , Bulgaria

Site Status

Arena 1409

Sofia, , Bulgaria

Site Status

Arena 1407

Sofia, , Bulgaria

Site Status

Arena 1425

Varna, , Bulgaria

Site Status

Arena 1202

Winnipeg, Manitoba, Canada

Site Status

Arena 1210

Bridgewater, Nova Scotia, Canada

Site Status

Arena 1208

Greater Sudbury, Ontario, Canada

Site Status

Arena 1209

Greater Sudbury, Ontario, Canada

Site Status

Arena 1206

London, Ontario, Canada

Site Status

Arena 1204

Toronto, Ontario, Canada

Site Status

Arena 1455

Prague, , Czechia

Site Status

Arena 1443

Amiens, , France

Site Status

Arena 1418

Clichy, , France

Site Status

Arena 1437

Lille, , France

Site Status

Arena 1476

Paris, , France

Site Status

Arena 1480

Pierre-Bénite, , France

Site Status

Arena 1423

Saint-Etienne, , France

Site Status

Arena 1457

Vandœuvre-lès-Nancy, , France

Site Status

Arena 1479

Hamburg, , Germany

Site Status

Arena 1422

Hamburg, , Germany

Site Status

Arena 1470

Hanover, , Germany

Site Status

Arena 1446

Kiel, , Germany

Site Status

Arena 1489

Leipzig, , Germany

Site Status

Arena 1497

Oldenburg, , Germany

Site Status

Arena 1444

Ulm, , Germany

Site Status

Arena 1478

Békéscsaba, , Hungary

Site Status

Arena 1431

Budapest, , Hungary

Site Status

Arena 1471

Budapest, , Hungary

Site Status

Arena 1492

Budapest, , Hungary

Site Status

Arena 1505

Debrecen, , Hungary

Site Status

Arena 1474

Debrecen, , Hungary

Site Status

Arena 1477

Szombathely, , Hungary

Site Status

Arena 1705

Beersheba, , Israel

Site Status

Arena 1702

Haifa, , Israel

Site Status

Arena 1706

Holon, , Israel

Site Status

Arena 1704

Jerusalem, , Israel

Site Status

Arena 1703

Petah Tikva, , Israel

Site Status

Arena 1462

Riga, , Latvia

Site Status

Arena 1475

Riga, , Latvia

Site Status

Arena 1484

Vilnius, , Lithuania

Site Status

Arena 1601

Christchurch, , New Zealand

Site Status

Arena 1439

Bydgoszcz, , Poland

Site Status

Arena 1486

Elblag, , Poland

Site Status

Arena 1495

Kielce, , Poland

Site Status

Arena 1451

Krakow, , Poland

Site Status

Arena 1438

Lodz, , Poland

Site Status

Arena 1458

Poznan, , Poland

Site Status

Arena 1428

Rzeszów, , Poland

Site Status

Arena 1456

Sopot, , Poland

Site Status

Arena 1494

Wroclaw, , Poland

Site Status

Arena 1491

Bucharest, , Romania

Site Status

Arena 1406

Bucharest, , Romania

Site Status

Arena 1441

Bucharest, , Romania

Site Status

Arena 1436

Iași, , Romania

Site Status

Arena 1420

Oradea, , Romania

Site Status

Arena 1405

Timișoara, , Romania

Site Status

Arena 1493

Timișoara, , Romania

Site Status

Arena 1500

Krasnoyarsk, , Russia

Site Status

Arena 1504

Novosibirsk, , Russia

Site Status

Arena 1419

Rostov-on-Don, , Russia

Site Status

Arena 1498

Saint Petersburg, , Russia

Site Status

Arena 1448

Saint Petersburg, , Russia

Site Status

Arena 1465

Samara, , Russia

Site Status

Arena 1615

Wŏnju, Gangwon-do, South Korea

Site Status

Arena 1614

Daegu, , South Korea

Site Status

Arena 1610

Incheon, , South Korea

Site Status

Arena 1403

Barcelona, , Spain

Site Status

Arena 1460

Barcelona, , Spain

Site Status

Arena 1481

Madrid, , Spain

Site Status

Arena 1430

Pontevedra, , Spain

Site Status

Arena 1432

Santiago de Compostela, , Spain

Site Status

Arena 1469

Seville, , Spain

Site Status

Arena 1424

Chernivtsi, , Ukraine

Site Status

Arena 1445

Ivano-Frankivsk, , Ukraine

Site Status

Arena 1454

Kharkiv, , Ukraine

Site Status

Arena 1459

Kharkiv, , Ukraine

Site Status

Arena 1466

Kiev, , Ukraine

Site Status

Arena 1411

Kiev, , Ukraine

Site Status

Arena 1408

Kyiv, , Ukraine

Site Status

Arena 1506

Kyiv, , Ukraine

Site Status

Arena 1414

Odesa, , Ukraine

Site Status

Arena 1433

Uzhhorod, , Ukraine

Site Status

Arena 1416

Vinnytsia, , Ukraine

Site Status

Arena 1501

Vinnytsia, , Ukraine

Site Status

Arena 1302

London, , United Kingdom

Site Status

Arena 1304

Torquay, , United Kingdom

Site Status

Arena 1303

Wolverhampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Bulgaria Canada Czechia France Germany Hungary Israel Latvia Lithuania New Zealand Poland Romania Russia South Korea Spain Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Vermeire S, Rubin DT, Peyrin-Biroulet L, Dubinsky MC, Regueiro M, Irving PM, Goetsch M, Lazin K, Gu G, Wu J, Modesto I, McDonnell A, Guo X, Green J, Dalam AB, Yarur AJ. Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 8;12(1):e001516. doi: 10.1136/bmjgast-2024-001516.

Reference Type DERIVED
PMID: 39778975 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APD334-005

Identifier Type: -

Identifier Source: org_study_id